What is B Positive Plasma?
Established in 2010, B Positive Plasma is dedicated to collecting high-quality plasma and other blood products essential for the creation of life-saving therapies. The company prioritizes donor safety and service quality, adhering to stringent regulations from bodies such as the FDA, PPTA, and OSHA. Operating as a crucial blood collection center in southern New Jersey, B Positive Plasma offers financial compensation to donors for their contributions, reinvesting these funds into the local community through charitable donations and support for local businesses. This commitment to both medical advancement and community enrichment defines their operational ethos.
How much funding has B Positive Plasma raised?
B Positive Plasma has raised a total of $4.3M across 2 funding rounds:
Private Equity
$3M
Debt
$1.3M
Private Equity (2016): $3M, investors not publicly disclosed
Debt (2021): $1.3M led by PPP
Key Investors in B Positive Plasma
PPP
Public-Private Partnership
What's next for B Positive Plasma?
The substantial enterprise-level funding indicates B Positive Plasma is poised for significant expansion and operational enhancement. This strategic backing will likely fuel advancements in their collection capabilities, potentially broadening their geographic reach and increasing their capacity to supply critical plasma-derived therapies. The company's focus on community reinvestment suggests a sustainable growth model that aligns corporate objectives with social responsibility, positioning them for continued success and impact in the healthcare sector.
See full B Positive Plasma company page
